Cannabis Science (CBIS) Congratulates U.S. Congress for Historical Move to Stop the Department of Justice (DOJ) Impeding Legal State Medical Cannabis Operations; Perfect Timing for CBIS Large Investment in California
PR Newswire - Mon Dec 15, 7:04AM CST
Cannabis Science, Inc. (OTCQB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, congratulates the U.S. Congress for making serious Medical Cannabis History by pulling this fiscal year's funding for any DOJ actions that would stop legal state medical cannabis programs and operations. The final bill passed the House last week and the Senate over the weekend.
OTC Daily Alert Stock Watch - Cannabis Science, Inc., (OTCQB: CBIS)
WorldStockWire - Mon Dec 15, 1:45AM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Cannabis Science (CBIS) Joins Forces With The Constituency For Africa (CFA) To Focus On Improving Healthcare Infrastructure In Africa In 2015
PR Newswire - Tue Dec 09, 6:01AM CST
Cannabis Science, Inc. (OTCQB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce its President & CEO, Mr. Raymond C. Dabney, along with CBIS's Senior Scientific Advisor, Dr. Roscoe M. Moore, Jr., have initiated a partnership between CBIS and the Constituency for Africa (CFA) to help improve the healthcare and health-related education infrastructure in Africa. The CFA, a Washington based education and advocacy organization, will focus attention on improving the healthcare infrastructure in Africa as part of its 2015 strategy. Founded in 1990, and now in its 25th year of operation, the CFA has emerged as a leading organization for mobilizing public and private support for Africa in Washington, DC. Please visit http://www.cfa-network.org for more information.
American Cannabis Company, A Delaware Corporation, Joins The List Of At Least 46 Other Marijuana Stocks
Anthony Cataldo - at Seeking Alpha - Sun Dec 07, 5:36PM CST
GWPH: 68.08 (+1.82), FULL: 4.76 (-0.01)
Cannabis Science (CBIS) Readies To Launch New Products In California With Apothocary Genetics
PR Newswire - Fri Dec 05, 6:33AM CST
Cannabis Science, Inc. (OTCQB: CBIS), a U.S. company specializing in global cannabis formulation-based drug development and consulting, is in the final stages of its preparations to launch new products throughout the California market, including extracts, oils, tinctures, tablets, and creams.
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2014
M2 - Wed Dec 03, 7:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/d3jpj5/basal_cell) has announced the addition of the "Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb - MediGene - Biofrontera - Novartis - 4SC - Transgene - Cannabis Science - Oncovir - Genextra For more information visit http://www.researchandmarkets.com/research/d3jpj5/basal_cell
BMY: 59.15 (-0.01), NVS: 93.91 (+0.66)
Lexaria: Moving Beyond the MMPR with PoViva
ACCESSWIRE - Mon Dec 01, 9:00AM CST
WHITEFISH, MT / ACCESSWIRE / December 1, 2014 / The medical use of marijuana has become well established over the past few years as clinical studies continue to demonstrate its potential in a number of areas. In fact, the U.S. government itself owns a patent titled Cannabinoids as antioxidants and neuroprotectants, which acknowledges the drug's potential in limiting neurological damage following ischemic insults like stroke and trauma.
GWPH: 68.08 (+1.82)
Strategic Review of Corn Starch Industry & Markets - Starch, Sweeteners, Bioprocessing & Co-Products 2014
PR Newswire Europe - Wed Nov 26, 8:01PM CST
Research and Markets ( http://www.researchandmarkets.com/research/vk...ic_review) has announced the addition of the "Strategic Review of Corn Starch Industry & Markets - Starch, Sweeteners, Bioprocessing & Co-Products 2014" [http://www.researchandmarkets.com/research/vk8bgt/strategic_review ] report to their offering.
Legal Marijuana Industry Outlook Positive As Advanced Technologies & Socially Acceptable Cannabis Products Lead to Increased Revenues
PR Newswire - Mon Nov 24, 9:57AM CST
Legal Marijuana & Cannabis Industry lean more toward heavily capitalized investors as Leading Technology & MMJ Manufacturers set sights on the Mainstream and becoming more socially acceptable. Major MMJ Companies in focus today are: Surna Inc. (OTC: SRNA), Medical Marijuana Inc. (OTC: MJNA), Hemp, Inc. (OTC: HEMP), Cannabis Science, Inc. (OTC: CBIS) and Nuvilex, Inc. (OTC: NVLX)
Cannabis Science (CBIS) Purchases Two Parcels of Cannabis Production Land from Apothecary Genetics, a Combined Total of 51 Acres; Licenses Land, Cultivation, and Formulation Usage in Major Growth Plan in California
PR Newswire - Mon Nov 24, 8:15AM CST
In a move that signals a forceful reinvestment in the largest legal medical cannabis market, Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in global cannabis formulation-based drug development and consulting, has successfully renegotiated its agreement with Apothecary Genetics Investments LLC to purchase and license two northern California production farms with a combined total of 51 acres. The purchase includes all related equipment for cannabis cultivation and production for the state's substantial medical cannabis market.
Cannabis Stocks Are On The Rise Following A Not So High Month Of October
ACCESSWIRE - Thu Nov 20, 8:30AM CST
CORAL GABLES, FL / ACCESSWIRE / November 20, 2014 / A marketwide trend swept the burgeoning marijuana sector in October and it seemingly occurred around the 15th of the month. With anticipation of the midterm elections and the uncertainty of how that would play out, investors played it close to the cuff and apparently felt more comfortable in a cash position when it came to trading marijuana stocks. Despite the anxieties surrounding a conservative republican majority, more states continue to legalize marijuana and thus stock prices have begun to climb back for some marijuana stocks over the last few weeks.
Cannabis Science Advances its Move into African Market from HIV to Cancer to the Ebola Virus With a Series of High-Level Meetings in Washington, D.C.
PR Newswire - Thu Nov 20, 6:17AM CST
As part of its multi-pronged move into Africa, the CEO of Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in global cannabis formulation-based drug development and consulting, joined a delegation lead by Melvin Foote, Founder, President & CEO of the Constituency for Africa (CFA) that met with Congresswoman Karen D. Bass (D-CA) and other key stakeholders.
Earth Science Tech's Pioneering CBD Work Spearheaded By Leading Cancer Treatment/Diagnostic Expert
ACCESSWIRE - Wed Nov 19, 3:07PM CST
WHITEFISH, MT / ACCESSWIRE / November 19, 2014 / A growing body of data from numerous studies over the past decade has gradually led to a more complete understanding of cannabinoid biology and pharmacology, including efficacy as an appetite stimulant, analgesic (pain reliever) and treatment for neurological disorders like epilepsy. Similar efficacy data regarding cannabinoids performing broad-spectrum anti-tumor functions and producing palliative effects on cancer symptoms, documented by the National Cancer Institute, has made cannabinoid science a hot property in the world of modern oncology medicine. Needless to say, the emerging market surrounding cannabinoids has been booming of late, with a variety of sector players seeing increased interest from investors, ranging from cannabis-based medicine developers like Cannabis Science (OTC: CBIS), to innovative medical cannabis-focused healthcare solution providers, like Novus Acquisition & Development (OTC: NDEV).
GWPH: 68.08 (+1.82)
Demand For Cannabis Science Drug Increases As Company Moves Into 2nd Stage Of Protocols For Pre-Clinical Drug Development, Thanks To Positive Laboratory Results From Its Operations In Spain
PR Newswire - Thu Nov 13, 1:07PM CST
Cannabis Science, Inc. (OTC: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce it is moving into 2nd stage cannabinoid production in Spain.
New Colombia Resources Inc. subsidiary, Sannabis SAS, Announces Product Line of Medical Marijuana Based Products in Colombia
PR Newswire - Wed Nov 12, 7:07AM CST
New Colombia Resources, Inc. (OTCQB: NEWC) ("New Colombia or the Company"
Cannabix Marijuana Breathalyzer Could Help Separate Users From Impaired
ACCESSWIRE - Mon Nov 10, 8:48AM CST
WHITEFISH, MT / ACCESSWIRE / November 10, 2014 / Federal Schedule I regulations on medical marijuana (MMJ) and recreational use are changing with each passing day as states continue to hammer out their own policy frameworks, spurred on by sizeable additions to state coffers as a result of tax revenues. Pew Research Center survey data from earlier this year also shows that for the first time since 1969, when only 12% of Americans favored legalization, more than half (54%) the country is now in favor of making marijuana legal. With 23 states and D.C. now having either some form of MMJ legislation, or open recreational use on the books (as in Colorado and Washington), cash-strapped state budget makers are likely looking closely at data points like the Denver Business Journal's analysis of Colorado's recreational market, which forecasts around $70M in tax revenues this fiscal year. In Oregon, where a ballot vote for legalization is set to take place in November, the state's Legislative Revenue Office estimates 2017 tax revenues at around $16M as a result. Recent in-depth analysis by NerdWallet even put the upper limit for Oregon around $100M per annum, and with a nationwide projection of as much as $3.1B, it seems clear that the tax revenue factor could lead to more easing from the feds. On November 4th, Washington D.C. voters looked to join Colorado and Washington State in legalizing adult-use marijuana after backing Initiative 71 at the voting booths. With voters backing the bill 7-to-3, the initiative will permit anyone over the age of 21 to legally possess as much as two ounces of marijuana and to grow up to three marijuana plants at home.
GWPH: 68.08 (+1.82)
Cannabis Science, Inc. (CBIS) Is In The Final Stages To Acquire A British Columbia Company That Has Submitted 'Marihuana for Medical Purposes' Application To Health Canada (As Previously Announced)
PR Newswire - Fri Nov 07, 1:32PM CST
Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce that as disclosed on August 25, 2014, the Company is in the final stages for the acquisition of a Marihuana for Medical Purposes (Canada) company, which has already submitted application to Health Canada (the "TargetCo"
Novus MedPlan Cost-Saving Provider Network Offers A Strong Value Proposition
ACCESSWIRE - Fri Nov 07, 8:01AM CST
WHITEFISH, MT / ACCESSWIRE / November 7, 2014 / Marijuana reform was a key ballot initiative in seven states (as well as 17 municipalities and D.C.) this week, with more drug policy reform questions (most aimed at reforming or out outright repealing marijuana laws) on the ballot than at any time in the history of the country. In California, Proposition 47 was passed, transforming the lowest-level non-violent crimes like simple drug possession, from a felony to a misdemeanor, freeing up an estimated $1B per annum to be dedicated to useful things like crime prevention, school funding, mental health treatment, and victim services. Regulatory reforms like this are opening up sizable markets for both private and public sector participants.
GWPH: 68.08 (+1.82)
Cannabis Science Announces Corporate Changes, Appointing Raymond Dabney As President And CEO And Dr. Dorothy Bray As Scientific Advisory Board Chair And Clinical Development Consultant
PR Newswire - Thu Nov 06, 5:45AM CST
Cannabis Science, Inc. (OTC: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce that some major corporate changes are taking place, allowing the Company to better position itself to face the continuing evolution of the industry and ongoing and incoming projects and initiatives.
Cannabis Science Enthused With CNN Monitoring The Outcome Of The National State By State Voting To Legalize Medical Cannabis
PR Newswire - Wed Nov 05, 12:53PM CST
Cannabis Science, Inc. (OTC: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is closely monitoring the CNN reporting of the outcome of the State by State voting to legalize medical cannabis. Target States in this voting session are Washington DC, Florida, Oregon, and Alaska.